Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis ; volume:73 ; number:12 ; day:16 ; month:10 ; year:2024 ; pages:1 ; date:12.2024
Cancer immunology immunotherapy ; 73, Heft 12 (16.10.2024), 1, 12.2024
- Urheber
-
Chen, Yueying
Han, Hedong
Cheng, Jing
Cheng, Qinpei
Zhu, Suhua
Zhan, Ping
Liu, Hongbing
Song, ·Yong
Lv, Tangfeng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-024-03819-x
- URN
-
urn:nbn:de:101:1-2502040910583.567548295378
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Yueying
- Han, Hedong
- Cheng, Jing
- Cheng, Qinpei
- Zhu, Suhua
- Zhan, Ping
- Liu, Hongbing
- Song, ·Yong
- Lv, Tangfeng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway